GlassScriptPhysician profile
Anna E Salvagno
NPI 1679191787
$9,339.81
in general payments reported to CMS, 2019-2025
26 companies · $2,535 in 2025
The $2,535 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $458 · 2022: $1,755 · 2023: $2,506 · 2024: $2,086 · 2025: $2,535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,126.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,040.61 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,733.86 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,156.23 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $643.83 | 2021-2025 | Dupixent |
| Amgen INC. | $535.42 | 2021-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $455.49 | 2022-2025 | |
| Biocryst US Sales Co., LLC | $408.29 | 2021-2025 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $319.00 | 2022-2025 | Cuvitru, Eohilia, Takhzyro |
| Ars Pharmaceuticals Operations, INC. | $255.10 | 2025 | Neffy |
| Grifols USA, LLC | $234.44 | 2022-2024 | Xembify, Prolastin-C Liquid |
| Pfizer INC. | $199.05 | 2022-2025 | |
| Leo Pharma INC. | $174.46 | 2022-2023 | Adbry |
| Csl Behring | $157.25 | 2022-2025 | Haegarda, Hizentra, Andembry |
| Genentech USA, INC. | $133.56 | 2023-2024 | Xolair |
| Alk-Abello, INC | $126.83 | 2021-2023 | Ragwitek, Odactra, Grastek |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $122.45 | 2022-2023 | |
| Kaleo, INC. | $109.95 | 2021-2024 | Auvi-Q |
| Blueprint Medicines Corporation | $103.37 | 2023-2024 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.26 | 2021-2023 | Spiriva Respimat |
| Incyte Corporation | $84.10 | 2021-2022 | |
| Pharming Healthcare, INC. | $82.96 | 2023-2025 | Ruconest |
| Ionis Pharmaceuticals, INC. | $58.80 | 2025 | Dawnzera |
| Galderma Laboratories, L.P. | $33.62 | 2025 | Nemluvio |
| Aimmune Therapeutics, INC. | $32.39 | 2021-2022 | |
| Lilly USA, LLC | $20.37 | 2024 | Ebglyss |
| Ani Pharmaceuticals, INC. | $15.12 | 2025 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Salvagno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.